Research Article
Treatment Outcomes of Hepatitis C-Infected Patients in Specialty Clinic vs. Primary Care Physician Clinic: A Comparative Analysis
Table 4
SVR outcomes based on the prescribed anti-HCV medication.
| Current treatment | GI clinic (noncirrhotic) Group-1 () | PCP clinic (noncirrhotic) Group-2 () | value | (%) of patients achieving SVR in GI clinic for the drug | (%) of patients achieving SVR in PCP clinic for the drug |
| Harvoni | 123 (64.06) | 144 (77.84) | <0.01 | 120 (97.56) | 134 (93.06) | Sofosbuvir+ribavirin | 33 (17.19) | 0 | | 32 (96.97) | 0 | Epclusa | 0 | 25 (13.51) | | 0 | 24 (96.00) | Viekira+ribavirin | 17 (8.85) | 0 | | 15 (88.24) | 0 | Zepatier | 0 | 15 (8.11) | | 0 | 14 (93.33) | Harvoni+ribavirin | 9 (4.69) | 1 (0.54) | | 7 (77.78) | 1 (100) | Sofosbuvir+Harvoni | 3 (1.56) | 0 | | 3 (100) | 0 | Sofosbuvir+simeprevir | 1 (0.52) | 0 | | 1 (100) | 0 | Daklinza+sofosbuvir | 1 (0.52) | 0 | | 1 (100) | 0 | Sofosbuvir+ribavirin+IFN | 1 (0.52) | 0 | | 1 (100) | 0 | Ledipasvir/sofosbuvir | 1 (0.52) | 0 | | 1 (100) | 0 | Viekira | 1 (0.52) | 0 | | 1 (100) | 0 | Technivie/ribavirin | 1 (0.52) | 0 | | 1 (100) | 0 | Harvoni/Viekira/Zepatier | 1 (0.52) | 0 | | 1 (100) | 0 |
|
|
Abbreviations: GI: gastroenterology; PCP: primary care physician; SVR: sustained virological response; IFN: interferon.
|